Neurology

SUDEP and overall mortality rates are substantial in DEEs, with syndrome differences.

In pooled RCTs and extensions of DEEs (n=3757), overall mortality was estimated at 8.76 per 1000 person-years. SUDEP incidence was estimated at 4.32 per 1000 person-years, accounting for roughly half of deaths overall. Subgroup rates varied: Dravet syndrome SUDEP was higher (7.59 per 1000 PY) versus LGS (3.4) and IESS (2.79). Authors caution that trial-based samples may underestimate real-world mortality and call for prospective population studies. 1

MSC therapy shows feasibility and short-term safety across neurological indications but heterogeneous efficacy.

Clinical MSC trials demonstrate feasibility and short-term safety across varied neurological disorders. Efficacy signals are heterogeneous and strongly dependent on disease stage and endpoint selection. Most robust motor signal cited was stereotactic SB623 implantation for chronic TBI, while ALS intrathecal data show early slope signals without durable benefit. Authors recommend adequately powered RCTs, disease-stage stratification, standardized rehabilitation, and transparent AE adjudication before clinical uptake. 2

Hypersexuality in neurology is often iatrogenic and requires structured, aetiology-driven assessment.

This systematic review (394 studies, 46,516 participants) found ≈61% of hypersexuality cases were iatrogenic, commonly from dopaminergic therapy in Parkinson disease. About 25% arose from focal lesions, TBI, or neurodegenerative syndromes, implicating fronto-striatal-limbic network dysfunction. Assessment practices were inconsistent; nearly half relied on unstructured clinical notes and informant input was rare. Authors urge structured, multimodal screening and aetiology-informed sequencing of reversible causes, behavioural strategies, and pharmacologic options. 3